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ABSTRACT
Introduction: Despite the proven efficacy 
of 3-hydroxy-3-methylglutaryl coenzyme A 
reductase inhibitors (statins) in lowering total 
and low-density lipoprotein cholesterol (LDL-C), 
many patients do not reach recommended lipid 
targets. This study compared pitavastatin, a new 
and highly effective statin, and simvastatin in 
patients at high risk of coronary heart disease 
(CHD). The primary objective was to demonstrate 
noninferiority of pitavastatin to simvastatin. 
Methods: The study was a phase 3, randomized, 
double-blind, double-dummy, parallel-group, 
active-controlled study conducted at 37 centers 
in five European countries. Following a dietary 
run-in period of 6-8 weeks, patients with 
primary hypercholesterolemia or combined 
dyslipidemia and at least two CHD risk factors 
were randomized 2:1 to receive pitavastatin 
4 mg or simvastatin 40 mg once daily for 
12 weeks. The primary efficacy variable was 
the change in LDL-C from baseline. Results: 
In total, 355 patients were randomized, 236 to 
pitavastatin and 119 to simvastatin; 330 patients 
(223 and 107, respectively) completed the study. 
In the pitavastatin group, mean (±SD) reduction 
in LDL-C concentrations from baseline was 
–44.0±12.8% compared with –43.8±14.4% in the 
simvastatin group. The adjusted mean treatment 
difference (simvastatin – pitavastatin) was 0.31% 
(95% confidence interval –2.47, 3.09; P=0.829), 
which was within the predefined noninferiority 
range. More than 80% of patients in each 
group reached recommended LDL-C targets. 
Pitavastatin provided a greater increase in high-
density lipoprotein cholesterol (HDL-C; 6.8% 
vs. 4.5%; P=0.083) and a significantly greater 
decrease in triglycerides (–19.8% vs. –14.8%; 
P=0.044) than simvastatin. Both treatments were 
well tolerated. Conclusion: Pitavastatin 4 mg is 
as effective as simvastatin 40 mg in lowering 
LDL-C in dyslipidemic patients at high risk of 
CHD, with additional effects on HDL-C and 
triglycerides. Therefore, pitavastatin may be 
appropriate for the management of dyslipidemic 
patients at high cardiovascular risk.
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INTRODUCTION
3-Hydroxy-3-methylglutaryl coenzyme A 
reductase inhibitors (statins) occupy a central 
place in the management of dyslipidemia due to 
their documented efficacy in lowering elevated 
total cholesterol and low-density lipoprotein 
cholesterol (LDL-C) concentrations and reducing 
cardiovascular mortality and morbidity. In a 
meta-analysis of 14 studies involving over 90,000 
patients who were followed for a mean of 5 years, 
statins were shown to reduce the risks of major 
vascular events, cardiac mortality, and overall 
mortality by 21%, 19%, and 12%, respectively, for 
each mmol/L decrease in LDL-C.1 Nevertheless, 
a significant proportion of dyslipidemic patients 
do not meet the lipid targets recommended in 
current consensus guidelines, despite treatment 
with statins.2-5 Thus, there is a need for more 
effective risk-management strategies to reduce the 
burden of cardiovascular mortality and morbidity 
associated with dyslipidemia. Such strategies 
could include the use of more aggressive initial 
therapy, more potent lipid-lowering agents, dose 
adjustment during treatment, or combination 
therapy using agents with different mechanisms 
of action.
Pitavastatin is a novel statin that has been 
shown to be more potent in lowering total 
cholesterol and LDL-C concentrations than 
simvastatin or pravastatin.6-8 In contrast to other 
statins, it undergoes limited metabolism by 
cytochrome P450 isoenzymes9,10 and, hence, the 
potential for interactions with drugs metabolized 
by these enzymes is low.11 
The present study was performed to compare 
the efficacy of pitavastatin and simvastatin in 
lowering LDL-C concentrations in patients 
at high risk of coronary heart disease (CHD). 
The primary objective was to demonstrate 
noninferiority of pitavastatin 4 mg once daily 
compared with simvastatin 40 mg once daily 
in reducing LDL-C concentrations. Secondary 
objectives were to assess the long-term efficacy 
of the two drugs in achieving the LDL-C targets 
recommended by the National Cholesterol 
Education Program (NCEP) Adult Treatment 
Panel III12 and the European Atherosclerosis 
Society (EAS),13 and to compare the effects of 
the two agents on other lipid measures and high 
sensitivity C-reactive protein (hs-CRP).
MATERIALS AND METHODS
Patients
Patients of either gender were eligible for inclusion 
in the study if they were aged 18-75 years
and had primary hypercholesterolemia 
or combined dyslipidemia that was un-
controlled (LDL-C ≥3.4 mmol/L [130 mg/dL] 
and ≤5.7 mmol/L [220 mg/dL]; triglycerides 
≤4.6 mmol/L [400 mg/dL]) despite dietary 
measures. In addition, patients were required to 
have at least two of the following cardiovascular 
risk factors: cigarette smoking; blood pressure 
of 140/90 mmHg or above or receiving 
antihypertensive therapy; a high-density 
lipoprotein cholesterol (HDL-C) concentration 
of 1 mmol/L (40 mg/dL) or below; a family 
history of CHD in a male or female first-degree 
relative below 55 or below 65 years of age, 
respectively; age above 45 years in men or above 
55 years in women. An HDL-C concentration 
above 1.55 mmol/L (60 mg/dL) was considered 
to offset one risk factor. Patients who were 
receiving lipid-modifying therapies were eligible 
for inclusion if such treatment was withdrawn at 
least 8 weeks before randomization.
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The principal exclusion criteria were 
homozygous familial hypercholesterolemia, 
unstable medical conditions, or conditions 
associated with secondary dyslipidemia, 
condi t ions  that  might  a f fec t  drug 
pharmacokinetics, significant cardiovascular 
disease, or symptomatic heart failure (left 
ventricular ejection fraction <0.25) or 
cerebrovascular disease, uncontrolled or poorly 
controlled hypertension, uncontrolled diabetes 
(>8% glycated hemoglobin), impaired liver 
or kidney function, or other serious medical 
conditions. Women of childbearing potential 
were required to have a negative pregnancy 
test at the start of the dietary run-in period and 
before starting treatment, and to use adequate 
contraception throughout the study.
The study was performed in compliance with 
the Declaration of Helsinki, the draft Note for 
Guidance on Clinical Investigation of Medicinal 
Products in the Treatment of Lipid Disorders 
by the Committee for Proprietary Medicinal 
Products, and the International Conference on 
Harmonization (ICH) of Technical Requirements 
for Registration of Pharmaceuticals for Human 
Use - Harmonized Tripartite Guidelines for Good 
Clinical Practice. The protocol was approved by 
local institutional review boards or independent 
ethics committees at each center. All participants 
provided written informed consent before 
inclusion in the study.
Study Design 
This was a phase 3, randomized, double-blind, 
double-dummy, parallel-group, active-controlled 
study conducted at 37 centers (predominantly 
in lipid clinics, cardiology clinics and university 
hospitals) in Denmark, the Netherlands, 
Spain, Sweden, and the United Kingdom. The 
study consisted of a 12-week initial treatment 
period (the core study) followed by a 44-week 
extension. This paper presents the results of the 
core study; the results of the extension phase 
will be reported separately.
Eligible patients entered a lead-in and wash-
out phase of 8 weeks if they had previously 
received lipid-modifying therapy or 6 weeks if 
they had not previously received such therapy. 
During this phase, and for the duration of the 
study, they followed a fat- and cholesterol-
restricted diet according to EAS guidelines. 
Patients received counseling to ensure that 
they adhered to this diet throughout the study. 
On completion of the run-in period, patients 
were randomized in a 2:1 ratio to receive 
pitavastatin 4 mg or simvastatin 40 mg once 
daily. Randomization was performed using an 
interactive voice recognition system at each 
center. Patients randomized to pitavastatin 
started treatment at a dose of 2 mg, and the dose 
was increased to 4 mg after 4 weeks. In patients 
randomized to simvastatin, the initial dose 
was 20 mg, which was increased to 40 mg after 
4 weeks. Treatment was given once daily in the 
evening, and all other lipid-modifying therapies 
were prohibited for the duration of the study. 
Compliance was checked by counting unused 
tablets or capsules at each study visit.
Both patients and investigators were blinded 
to the treatment received. Because pitavastatin 
is given in tablet form, and simvastatin in 
capsule form, blinding was maintained by the 
use of placebo dummies, which were identical 
in appearance to the active medications. 
Pitavastatin tablets (2 and 4 mg) and matching 
placebos were supplied by SkyePharma 
Production (Saint Quentin-Fallavier, France), 
and over-encapsulated simvastatin tablets and 
matching placebos by ALMAC (Craigavon, UK). 
Blood samples for lipid analyses were 
obtained after a 12-hour fast on three occasions 
during the run-in period and at weeks 0, 2, 4, 8, 
and 12 of the study. 
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Outcome Measures
The primary efficacy endpoint was the 
percentage change in LDL-C concentrations at 
12 weeks compared with baseline. Secondary 
efficacy endpoints included the proportion 
of patients reaching NCEP and EAS LDL-C 
targets, percentage changes from baseline in 
concentrations of triglycerides, total cholesterol, 
HDL-C, non-HDL-C, apolipoprotein B (Apo-B) 
and apolipoprotein A1 (Apo-A1), and absolute 
changes from baseline in concentrations of 
oxidized LDL (measured using an enzyme-linked 
immunosorbent assay), and hs-CRP and ratios of 
total cholesterol:HDL-C, non-HDL:HDL-C, and 
Apo-B:Apo-A1. All lipid analyses were performed 
at a central laboratory.
Safety and Tolerability
Treatment-emergent adverse events (TEAE), 
defined as any event with onset on or after 
the first dose of study drug, and serious TEAE 
were recorded throughout the study. All such 
events were coded by system organ class 
preferred terms using the Medical Dictionary 
for Regulatory Activities. Clinical laboratory 
safety assessments included routine blood 
chemistry, hematology, urinalysis, liver enzymes 
(alanine aminotransferase and aspartate 
aminotransferase), and creatine kinase (CK). 
Other safety evaluations included physical 
examination, 12-lead electrocardiogram (ECG), 
and vital signs.
Statistical Analyses
The planned target size for the core study was 
300 patients (200 randomized to pitavastatin 
and 100 randomized to simvastatin). It 
was calculated that this sample size would 
provide at least 99% power to reject the null 
hypothesis that the mean percentage decrease 
in LDL-C concentrations from baseline would 
be at least 6% greater in the simvastatin group 
than in the pitavastatin group, assuming a 
standard deviation (SD) of 12 (for percentage 
decrease from baseline LDL-C) and a one-tailed 
significance level of 2.5%. 
The noninferiority analysis and other lipid 
assessments were performed on the full analysis 
set (FAS), which included all randomized 
patients who received at least one dose of 
study medication and had at least one lipid 
assessment during the study. Confirmatory 
analyses were performed on the per-protocol 
(PP) population, which included all patients in 
the FAS who had a lipid assessment at week 12 
and no major protocol deviations. The primary 
efficacy variable was the change in LDL-C 
from baseline to endpoint for the FAS, or from 
baseline to week 12 for the PP population. The 
baseline measurement was defined as the mean 
of the three measurements made during the 
run-in period, while the endpoint was defined 
as the week 12 measurement or the last available 
measurement in patients who withdrew from 
the study prematurely. Differences in this 
primary efficacy endpoint between groups 
were analyzed by analysis of covariance 
(ANCOVA), with treatment and country as 
factors and baseline LDL-C as a covariate. The 
adjusted mean difference between treatments 
(simvastatin 40 mg minus pitavastatin 4 mg) 
and the corresponding 95% CI were calculated. 
Pitavastatin was considered noninferior 
(equivalent) to simvastatin if the lower limit of 
the 95% CI was greater than –6%. Prospectively 
planned subgroup analyses based on age, 
gender, race, body mass index (BMI), diagnosis, 
risk category, baseline LDL-C concentration, 
and presence of hypertension and diabetes were 
conducted using the same model. Secondary 
efficacy variables were also evaluated using 
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ANCOVA and 95% CIs on the adjusted mean 
differences in the absolute or percentage changes 
from baseline to endpoint for the FAS, and to 
week 12 for the PP population. Noninferiority 
margins for secondary variables were not 
defined. All analyses were performed using SAS®
Version 8.2 software (SAS Institute Inc., Cary, 
NC, USA).
RESULTS
Patient Flow and Baseline Characteristics
The first patient was enrolled on September 
27, 2005 and the final patient visit took place 
on October 2, 2006. In total, 355 patients were 
randomized, of whom 236 received pitavastatin 
and 119 received simvastatin (Figure 1). Three 
patients in the pitavastatin group were excluded 
from the FAS and safety population because 
they did not receive any study medication: two 
patients withdrew consent and the third was 
withdrawn because of protocol violations. One 
patient in the simvastatin group was excluded 
from the FAS because of no on-treatment lipid 
assessment. Overall, 330 patients (223 in the 
pitavastatin group, 107 in the simvastatin group) 
completed the 12-week study. 
The two groups were well matched in terms 
of their baseline characteristics (Table 1). The 
mean age of the patients was approximately 
60 years, about two-thirds were male, and all 
except one were White. The majority of patients 
(>80%) had primary hypercholesterolemia, 
and approximately three-quarters were at 
moderate or high cardiovascular risk according 
to the NCEP criteria. Weight was similar 
between the pitavastatin and simvastatin 
groups at the screening visit and did not change 
significantly during the study (pitavastatin: 
Figure 1. Patient disposition by treatment group and analysis population. *One patient excluded from the full analysis set 
















No week 12 lipid assessment: n=14
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screening=80.8±13.5 kg; week 12=79.9±13.7 kg; 
simvastatin: screening=80.9±12.8 kg; week 
12=80.1±11.9 kg). Similar percentages of 
patients in each treatment group were receiving 




In the pitavastatin group, mean (±SD) 
LDL-C concentrations decreased from 
4 .30±0 .52 mmol /L  a t  ba s e l ine  to 
2.40±0.61 mmol/L at endpoint, corresponding 
to a percentage decrease of –44.0±12.8%. In 
simvastatin-treated patients, LDL-C decreased 
from 4.32±0.61 mmol/L to 2.41±0.64 mmol/L, 
corresponding to a reduction of –43.8±14.4%. 
The adjusted mean treatment difference 
(simvastatin minus pitavastatin) was 0.31% 
(95% CI: –2.47, 3.09), which was within the 
predefined limits of noninferiority (P=0.829 
for treatment difference). These results were 
confirmed in the PP analysis, which yielded a 
mean treatment difference of –0.61% (95% CI: 
–3.17, 1.94; P=0.637).
The mean reduction in LDL-C concentration 
was approximately 35% in both treatment 
groups after 2 weeks of treatment, and 
LDL-C continued to decrease throughout the 
study (Figure 2). Preplanned analyses were 
performed to compare the reductions in LDL-C 
concentration achieved with both treatments 
in different patient subgroups, based on age, 
gender, BMI, primary diagnosis, baseline 
LDL-C, NCEP CHD risk, and the presence of 
hypertension or diabetes (Figure 3). The only 
significant difference found in these analyses 
was a greater reduction in LDL-C concentration 
with simvastatin compared with pitavastatin in 
patients aged 65 years and over, who accounted 
for 23% of the overall study population. 
Table 1. Baseline demographic and clinical characteristics 
(safety population). 
Characteristic Pitavastatin Simvastatin 
  4 mg 40 mg
  (n=233) (n=119)
Gender 
 Male, n (%) 158 (67.8) 82 (68.9)
 Female, n (%) 75 (32.2) 37 (31.1)
Age (years), mean ± SD 60.1±6.8 60.9±6.8
Age group, n (%)  
 <65 years 184 (79.0) 88 (73.9)
 ≥65 years 49 (21.0) 31 (26.1)
Race, n (%)  
 White 233 (100) 118 (99.2)
 Black 0 (0.0) 1 (0.8)
Primary diagnosis, n (%)  
 Primary hyper- 
 cholesterolemia 194 (83.3) 102 (85.7)
 Combined dyslipidemia 35 (15.0) 14 (11.8)
 Heterozygous FH 4 (1.7) 3 (2.5)
Time since diagnosis (years), 
mean ± SD 3.7±5.4 4.5±6.0
Height (m), mean ± SD 1.7±0.1 1.7±0.1
Weight (kg), mean ± SD 80.8±13.5 80.9±12.8
Body mass index (kg/m2), 
mean ± SD 27.6±3.5 27.6±3.2
NCEP risk category, n (%)  
 High 59 (25.3) 35 (29.4)
 Moderate 165 (70.8) 79 (66.4)
 Low 9 (3.9) 5 (4.2)
Diabetes, n (%) 15 (6.4) 8 (6.7)
Hypertension, n (%)  123 (52.8) 70 (58.8)
Clinical CHD, n (%) 16 (6.9) 11 (9.2)
Concomitant medication, 
n (%)* 192 (82.4) 95 (79.8)
 Total 26 (11.2) 12 (10.1)
 ACE inhibitors (single) 9 (3.9) 4 (3.4)
 ACE inhibitors 
 (combination) 20 (8.6) 14 (11.8)
 Angiotensin II antagonists 
 (single) 16 (6.9) 10 (8.4)
 Angiotensin II antagonists 
 (combination) 41 (17.6) 17 (14.3)
 Beta-blockers 29 (12.4) 22 (18.5)
 Calcium channel blockers 34 (14.6) 21 (17.6)
 Diuretics 39 (16.7) 26 (21.8)
*Total number of patients on concomitant medication and 
numbers on antihypertensive medications are listed.
ACE=angiotensin-converting enzyme inhibitor; 
CHD=coronary heart disease; FH=familial 
hypercholesterolemia; NCEP=National Cholesterol 
Education Program; SD=standard deviation.
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Attainment of EAS and NCEP Lipid Targets
NCEP targets for LDL-C concentrations were 
achieved by 203 of 233 (87.1%) patients in the 
pitavastatin group, and 101 of 118 patients 
(85.6%) in the simvastatin group. The numbers 
of patients achieving the EAS targets for LDL-C 
concentration were 203 (87.1%) and 96 (81.4%) 
for the pitavastatin and simvastatin groups, 
respectively. The mean treatment differences 
in the proportion of patients achieving LDL-C 
targets were –1.5% (95% CI: –9.2, 6.1; P=0.695) 
for the NCEP targets and –5.8% (95% CI: –14.0, 
2.5; P=0.170) for the EAS targets.
Secondary Efficacy Variables
Mean percentage changes in secondary lipid 
variables (concentrations of triglycerides, total 
cholesterol, HDL-C, non-HDL-C, triglycerides, 
Apo-B, and Apo-A1) and absolute changes in 
oxidized LDL concentration, non-HDL:HDL-C 
ratio, Apo-B:Apo-A1 ratio, and hs-CRP level 
from baseline are summarized in Table 2. 
Pitavastatin provided a significantly greater 
reduction in triglycerides than simvastatin 
(–19.8% vs. –14.8%; P=0.044), and there 
was also a greater increase in HDL-C with 
pitavastatin (6.8% vs. 4.5%), which was not 
statistically significant (P=0.083). There were no 
other significant differences in secondary lipid 
measures between the two groups.
Safety and Tolerability
TEAE
TEAE were reported by 119 patients (51.1%) 
in the pitavastatin group and by 60 patients 
(50.4%) in the simvastatin group (Table 3). 
Adverse events that were considered to be 
treatment related occurred in 33 (14.2%) and 
26 (21.8%) patients in the pitavastatin and 
simvastatin groups, respectively. The most 
common TEAE (those occurring in ≥2% of 
patients in either group) are summarized in 
Table 3. Constipation occurred in 4.3% of 
patients receiving pitavastatin and in 1.7% of 
those receiving simvastatin, and was considered 
to be treatment related in 3.9% and 0.8%, 
respectively. Myalgia was reported as a TEAE by 
seven pitavastatin-treated patients (3.0%) and 
by five simvastatin-treated patients (4.2%), and 
was considered to be treatment-related in four 
(1.7%) and three (2.5%) patients, respectively. 
Most TEAE were mild or moderate in severity. 
A total of 15 patients discontinued treatment 
because of TEAE; of these, nine (3.9%) were 
receiving pitavastatin and six (5.0%) were 
receiving simvastatin. The most common 
adverse event leading to treatment withdrawal 
was nausea, which occurred in three patients, 
all of whom were receiving simvastatin.
Four serious TEAE (gastritis, peritonsillar 
abscess, myocardial infarction, and acute 
coronary syndrome) occurred in patients in 
the pitavastatin group, and five serious TEAE 
(cholelithiasis, cystitis, aortic aneurysm, 
syncope, and lymphadenopathy) were reported 
in the simvastatin group. None of these events 
were considered to be treatment related.
Figure 2. Mean percentage reduction in low-density 
lipoprotein cholesterol (LDL-C) concentrations from 
baseline at weeks 2, 4, 8, and 12 of treatment with 
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Laboratory Abnormalities
Three of the 12 patients in whom myalgia was 
reported as an adverse event showed elevated 
CK levels during the study. One patient in 
the simvastatin 40 mg group had elevated CK
at baseline, which resolved during subsequent 
treatment, and one patient in each group 
developed elevated CK during treatment. 
Three patients in the pitavastatin group 
developed asymptomatic elevations of CK
to more than five times the upper limit of
the normal range (ULN), as did one simvastatin-
treated patient. No patient showed elevations 
of liver enzymes above three times the
ULN. There were no other cl inically
Figure 3. Subgroup analysis of reductions in low-density lipoprotein cholesterol (LDL-C) concentrations from baseline to 
12 weeks of treatment with pitavastatin 4 mg or simvastatin 40 mg. Values are means ± standard deviation for the number 
of patients in parentheses. *P=0.024 compared with pitavastatin. CHD=coronary heart disease; Combined dys=combined 
dyslipidemia; Het FH=heterozygous familial hypercholesterolemia; Primary HC=primary hypercholesterolemia; 
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relevant findings on clinical laboratory 
evaluation, physical examination, vital signs, 
or ECG.
Mean plasma glucose levels did not change 
during the study in the groups treated with 
pitavastatin (baseline=98.4±14.5 mg/dL; week 12 
Table 2. Changes from baseline in secondary lipid variables and high sensitivity C-reactive protein (hs-CRP) in patients 
treated with pitavastatin or simvastatin. 
Parameter Change from baseline (mean ± SD)*   
  Pitavastatin Simvastatin Adjusted mean treatment
  4 mg (n=233) 40 mg (n=118) difference (95% CI) P-value
Total cholesterol
 Baseline (mmol/L) 6.37±0.66 6.35±0.78
 Change (%) –31.4±9.4 –31.2±11.1 0.28 (–1.79, 2.34) 0.793
HDL-C
 Baseline (mmol/L) 1.22±0.29 46.0±8.2
 Change (%) 6.8±12.6 4.5±12.1 –2.30 (–4.91, 0.30) 0.083
Non-HDL-C
 Baseline (mmol/L) 5.14±0.65 5.16±0.76
 Change (%) –40.4±11.7 –39.2±13.4 1.35 (–1.17, 3.87) 0.293
Non-HDL-C:HDL-C ratio
 Baseline 4.45±1.25 4.50±1.09
 Change (%) –1.9±0.9 –1.9±0.9 0.073 (–0.07, 0.22) 0.319
Total cholesterol:HDL-C ratio
 Baseline 5.45±1.25 5.50±1.09
 Change (%) –1.9±0.9 –1.9±0.9 0.073 (–0.07, 0.22) 0.319
Triglycerides 
 Baseline (mmol/L) 1.85±0.77 1.85±0.75
 Change (%) –19.8±21.3 –14.8±29.7 5.23 (0.15, 10.30) 0.044
Apo-B 
 Baseline (mg/dL) 152.5±20.9 153.3±24.6
 Change (%) –33.7±12.3 –33.8±12.9 0.46 (–2.15, 3.07) 0.730
Apo-A1
 Baseline (mg/dL) 158.4±26.1 155.5±20.8
 Change (%) 7.6±12.7 6.9±12.1 –1.28 (–3.86, 1.30) 0.330
Apo-B:Apo-A1 ratio
 Baseline 0.99±0.24 1.00±0.20
 Change (%) –0.4±0.2 –0.4±0.2 0.00 (–0.03, 0.04) 0.929
Oxidized LDL
 Baseline (U/L) 80.4±16.2 81.5±16.5
 Change (%) –25.5±16.3 –25.9±17.1 0.40 (–2.21, 3.02) 0.761
hs-CRP
 Baseline (mg/L) 3.21±4.89 3.77±7.93
 Change (%) –0.4±6.0 0.1±5.5 0.48 (–0.81, 1.78) 0.462
*Mean individual changes from baseline are given in terms of percentages or actual values as indicated.
Apo-A1=apolipoprotein A1; Apo-B=apolipoprotein B; CI=confidence interval; HDL-C=high-density lipoprotein 
cholesterol; LDL-C=low-density lipoprotein cholesterol; SD=standard deviation.
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or last visit=98.4±15.9 mg/dL) or simvastatin 
(baseline=101.7±19.0 mg/dL; week 12 or last 
visit=101.1±18.0 mg/dL). Likewise, there was 
no indication of a treatment-related increase 
in urinary protein excretion (assessed by the 
protein:creatinine ratio) in either group.
DISCUSSION
This randomized trial has shown that 
pitavastatin 4 mg is noninferior to simvastatin 
40 mg for lowering LDL-C concentrations in 
patients with primary hypercholesterolemia or 
combined (mixed) dyslipidemia who are at high 
risk of CHD. Simvastatin is a standard treatment 
in this patient population, based on studies 
such as the Heart Protection Study,14 which 
showed that simvastatin 40 mg reduced the 
incidence of myocardial infarction, stroke, and 
revascularization by about one-third in high-
risk patients. The present study is, therefore, 
consistent with other studies, which suggest that 
pitavastatin is an effective and well-tolerated 
statin that is potentially suitable for primary 
or secondary prevention of CHD in a broad 
range of patients.8,9,15 Further studies to assess 
morbidity and mortality are currently underway 
in Japan to determine the long-term efficacy and 
safety of pitavastatin.
A high proportion (81%-87%) of patients 
in both treatment groups achieved the LDL-C 
targets recommended in the NCEP and EAS 
guidelines. This figure is considerably higher 
than those reported in observational studies in 
Europe, in which approximately 55% of patients 
did not attain recommended LDL-C targets 
despite receiving lipid-modifying therapy.3,5,16 
This commonly observed discrepancy 
suggests that more aggressive therapy or dose 
adjustment may be necessary to achieve lipid 
targets in routine clinical practice. The present 
findings suggest that a high proportion of 
patients can be brought to their cholesterol 
targets with pitavastatin. Moreover, the results 
of the extension study suggest that LDL-C 
concentrations are also maintained at target 
levels during long-term treatment, with little 
need for dose adjustment, in the majority of 
patients.17
Although pitavastatin and simvastatin had 
similar effects on LDL-C concentrations in this 
study, there were differences in their effects on 
secondary lipid measures. Pitavastatin 4 mg 
provided a larger increase than simvastatin in 
HDL-C concentrations, although the difference 
was not statistically significant. This is consistent 
with the results of other studies, showing that 
pitavastatin consistently increases HDL-C 
concentrations,15 with other statins having more 
variable effects.18 Whereas most statins increase 
HDL-C concentrations by inhibiting cholesteryl 
ester transfer protein and stimulating Apo-A1 
synthesis,18 there is evidence that pitavastatin 
increases HDL-C by increasing Apo-A1 and 
Table 3. Summary of treatment-emergent adverse 
events (TEAE) in patients treated with pitavastatin or 
simvastatin. 
  Number (%) of patients 
  with a TEAE
  Pitavastatin Simvastatin
  4 mg 40 mg 
  (n=233) (n=119)
Any TEAE 119 (51.1) 60 (50.4)
Serious TEAE 4 (1.7) 5 (4.2)
Treatment-related TEAE 33 (14.2) 26 (21.8)
Discontinuations due 
to TEAE 9 (3.9) 6 (5.0)
TEAE occurring in ≥2% of patients in either group
 Headache 13 (5.6) 3 (2.5)
 Nasopharyngitis 11 (4.7) 3 (2.5)
 Constipation 10 (4.3) 2 (1.7)
 Myalgia 7 (3.0) 5 (4.2)
 Back pain 4 (1.7) 3 (2.5)
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ATP-binding cassette transporter (also known as 
cholesterol efflux regulatory protein) levels.19,20
Further studies are needed to characterize the 
different effects of various statins on HDL-C 
concentrations, and their underlying molecular 
mechanisms.
Pitavastatin had a significantly greater effect 
than simvastatin on triglycerides, producing 
a mean reduction of approximately 20% from 
baseline. Triglycerides have been shown to 
be an independent risk factor for CHD,21 and 
hence differences between statins in their ability 
to lower triglyceride concentrations may be 
clinically relevant. The potential importance of 
the effects of statins on HDL-C and triglyceride 
levels was highlighted by an analysis of 
secondary outcomes in the Scandinavian 
Simvastatin Survival Study (4S), which showed 
that the risk reductions in cardiovascular 
mortality and morbidity achieved with 
simvastatin were significantly greater (P=0.03) 
in patients with the lowest HDL-C and highest 
triglyceride levels, compared with patients with 
the highest HDL-C and the lowest triglyceride 
levels.22
Both treatments were well tolerated. The 
adverse event profiles of pitavastatin and 
simvastatin were similar, and there were no 
notable differences in the incidence of muscular 
adverse events (such as myalgia) and liver 
enzyme elevations. This is consistent with 
previous trials that have shown a favorable 
safety and tolerability profile of pitavastatin in a 
broad range of patients.8,9,15
The limitations of this study should be 
noted. The protocol was developed to compare 
pitavastatin 4 mg with simvastatin 40 mg (the 
most commonly prescribed statin regimen), and 
the effects of simvastatin 80 mg daily were not 
evaluated. The patient population was primarily 
White, and so caution should be exercised in 
extrapolating the results to, for example, Black 
patients, who were not represented in this 
study. Also, only four of the patients who were 
given pitavastatin, and three who were given 
simvastatin, were diagnosed with heterozygous 
familial hypercholesterolemia, making it 
difficult to interpret the increases seen in this 
small subgroup of patients. Finally, although 
pitavastatin 4 mg provided larger increases in 
HDL-C and reductions in triglyceride levels 
than simvastatin 40 mg in this study, large-
scale studies with sufficient statistical power 
to evaluate effects on clinical outcomes are 
required to determine the clinical relevance of 
these differences.9
CONCLUSION
In conclusion, this study has shown that 
pitavastatin 4 mg is as effective as simvastatin 
40 mg in lowering LDL-C concentrations in 
dyslipidemic patients at high risk of CHD, and 
also has effects on other lipid fractions, notably 
HDL-C and triglycerides. More than 80% of 
pitavastatin-treated patients reached the NCEP 
and EAS targets for LDL-C. These findings 
suggest that pitavastatin is an appropriate agent 
for the management of dyslipidemia in patients 
at high cardiovascular risk. Further outcome 
studies, however, with hard clinical endpoints, 
both in terms of cardiovascular events and safety 
– including liver and muscle toxicity – will be 
required to confirm the long-term benefits of 
pitavastatin. 
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